TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: BES, EES, and ZES-R in Real World Practice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Age \> 19 years~* Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure~* Subject must have significant stenosis (\>50% by visual estimate) on a native or in-stent coronary artery~* Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, acute myocardial infarction, positive functional study or a reversible changes in the ECG consistent with ischemia). In subjects with coronary artery stenosis \>75%, evidence of myocardial ischemia does not have to be documented~Exclusion Criteria~* Subject has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9, everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients with documented sensitivity to contrast media, which can be effectively premedicated with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis to prior contrast media should not be enrolled.)~* Subject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within 12 months.~* Female subject of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study~* Subject planned an elective surgical procedure that would necessitate interruption of antiplatelet during the first 12 months post enrollment~* Subject with non-cardiac co-morbid condition with life expectancy \< 2 year or that may result in protocol non-compliance (per site investigator's medical judgment)~* Subject with cardiogenic shock at presentation~* Subject who are actively participating in another drug or device investigational study, who have not completed the primary end point follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biolimus-eluting stent (Type: ACTIVE_COMPARATOR): Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
- Everolimus-eluting stent (Type: ACTIVE_COMPARATOR): Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
- Zotarolimus-eluting stent (Type: ACTIVE_COMPARATOR): Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-hospital and Intra-hospital Temporal Delays in Patients Requiring Emergent Trauma Craniotomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* every patient undergoing 1 of 3 surgical procedures ('removal of epidural hematoma'; 'removal of acute subdural hematoma'; and 'decompressive craniectomy'), performed between February 1, 2010 and January 31, 2016, as recorded in the surgical database of our institution.~Exclusion Criteria:~* who had a delayed clinical or radiological deterioration as a surgical indication;~* who did not have traumatic brain injury as the origin of the intracranial abnormalities;~* in whom not all aforementioned temporal or clinical data were readily available from the electronic patient file; and/or~* who were not admitted via our emergency department.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Guided Biopsy for Mapping Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed diagnosis of prostate cancer~* Patients must have elected to undergo radical prostatectomy using an open, laparoscopic or robotic approach~* Patients must be at least 18 years of age and able to provide written informed consent.~* No history of radiotherapy, chemotherapy or hormone therapy within 6 months of surgery~* Primary tumor must be amenable to surgical removal for curative intent~* Patients must have ECOG-performance status 0 or 1 (appendix II)~* Patients must have no history of rectal or anal disease.~* Patients must have adequate organ function as defined by the following criteria:~  * Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x ULN if liver function abnormalities are due to underlying malignancy~ * Total serum bilirubin ≤1.5 x ULN~ * Absolute neutrophil count(ANC)≥1,500/microL~ * Platelets≥lOO,OOO/microL~ * Hemoglobin≥9.0 g/dL~ * Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal albumin - serum albumin)x 0.8)~ * Patients must have serum creatinine\<2 mg/dL or serum creatinine clearance (CrCl)\>40ml/min(CrCl= Wt(kg)x(140-age)\*/72xCr. level,\*female x 0.85)~Inclusion of minorities:~* Members of all races and ethnic groups are eligible for this trial. Women and children are not eligible since prostate cancer is not diagnosed in these groups.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate cancer (Type: EXPERIMENTAL): A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of a Currently Marketed Hearing Aid Programmed With Two Different Fitting Methods

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All types of hearing loss (sensorineural, conductive, mixed)~* If the hearing loss is conductive or mixed it must first be approved for amplification by a physician~* All shapes of hearing loss (flat, sloping, reverse slope, notch)~* Severity ranging from mild to severe~* First time hearing aid users (never worn hearing aids before)~* German speaking~* Both genders~* Ages 18 and older~* Ability and willingness to sign the consent form~Exclusion Criteria:~* Current hearing aids users~* Contraindications for amplification~* Active ear disease~* Inability to follow the procedures of the study due to language problems, psychological disorders, dementia, or other cognitive problems of the participant~* A reduced mobility unable to attend weekly study appointments~* A reduced ability to describe auditory impressions and the usage of the hearing aids~* Uncooperative so that it is not possible to record a valid pure tone audiogram~* A strongly reduced dexterity~* With psychological problems~* Central hearing disorders~* Bernafon employees~* Family members of Bernafon employees

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fitting System (Type: EXPERIMENTAL): a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
- Traditional Fitting System (Type: ACTIVE_COMPARATOR): A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Diabetic Cardiac Stress Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patient older than 18 years old~* Patient with health care coverage ( social security or universal health coverage - CMU)~* Patient who had a prior medical examination~* Diabetic patient (type 1 or type 2) with no known coronary artery disease, addressed for myocardial scintigraphy~* Patient who was informed of objectives and constraints of the study and having given his consent in writing~EXCLUSION CRITERIA:~* Pregnant and lactating women~* Patients with known coronary disease (myocardial infarction, unstable angina, history of coronary artery disease)~* Patient with contra-indication for MRI claustrophobia, metallic foreign body in the eye, pacemakers, mechanical heart valve laid before 1985 Patient with specific contra-indication to vasodilators~* Severe hypotension \< 90 mmHg~* Hypersensitivity to adenosine or dipyridamole~* Bronchial asthma, chronic obstructive pulmonary disease with obvious bronchospasm. Severe and known pulmonary artery hypertension~* Atrioventricular 2nd or 3rd degree blocks, long QT syndrome~* Tight known carotid artery stenosis (70% NASCET criterion), with no possible vascular substitution~* Patient with contra-indication to cardiac stimulation~* Unstable hemodynamic state and / or unstable angina not stabilized by drug treatment and/or decompensated or severe heart failure~* Known comorbidities : pregnancy and lactation, tight aortic valve or mitral valve stenosis, severe left-right shunt, severe pericarditis or abundant pericardial effusion~* Contra-indication to coronary angiography~* Renal failure with creatinine clearance \< 30 ml / min~* Hypersensitivity to contrast agents that resulted in a serious complication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~* Diabetic patients~* Coronary insufficiency

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Subclinical Hyperthyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 50 and greater~* Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels~Exclusion Criteria:~* Iodide overload~* Non sinusal heart rhythm~* Severe heart disease

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥70 years patients with coronary artery disease (≤stable angina CCS III, Unstable angina IIb~* patients with signed informed consent~* significant coronary artery stenosis (\>50%) considered for coronary stenting~* Reference vessel diameter of 2.5 to 4.0 mm~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Everolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)~* Systemic (intravenous) Everolimus use within 12 months~* The patients who are receiving anticoagulants or anti-platelet medications besides aspirin \& clopidogrel~* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions~* Baseline hemogram with Hb\<10g/dL or PLT count \<100,000/μL~* Severe Hepatic dysfunction (≥ 3 times normal reference values)~* Significant renal dysfunction (Serum creatinine ≥ 2.0 mg/dl)~* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months~* Patients with LV systolic dysfunction (LVEF\<40%) or in cardiogenic shock~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period~* An elective surgical procedure is planned that would necessitate interruption of DAPT during the first 12 months post enrollment

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genous stent group (Type: ACTIVE_COMPARATOR): Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
- Xience stent group (Type: ACTIVE_COMPARATOR): Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
- Atorvastatin 20mg group (Type: ACTIVE_COMPARATOR): None
- Atorvastatin 80mg group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with suspected AD, MCI and other cognitive impairment will be referred by their neurologist to have a clinical ordered FDG-PET/CT and clinically indicated AMYVID in addition,~* Patients equal to or greater than 21 years old,~* Signed informed consent by patient or legal guardian,~* Physically capable to cooperate.~Exclusion Criteria:~* Subjects who do not meet the above mentioned inclusion criteria,~* Subjects unwilling or unable to sign the informed consent form,~* Subjects with any significant psychiatric or neurologic disorder or disease other than dementia expected to interfere with the study,~* Subjects unable to undergo MR scanning due to exclusion via UHCMC MR restrictions (e.g. certain implanted metallic or electronic devices),~* History of adverse events related to a previous MR or PET/CT,~* Pregnant women,~* Minors.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT vs. PET/MRI (Type: OTHER): Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Crohn Disease with curative ileocolonic resection~* Randomization within 45 days from ileocolonic resection or end or loop ileostomy within last year and closure occurred within 45 days from randomization~* Fecal stream restoration at least 14 days prior to randomization~* Presence of at least one risk factor for recurrence~* Pregnancy protection on board during the study for childbearing female subjects~Exclusion Criteria:~* Presence of CD proximally or distally to the site of resection~* Patients with strictureplasties at index surgery or ileorectal anastomosis~* patients with active perianal CD~* Patient treated with other treatments usually utilised for CD~* Patients with active diseases with gastrointestinal involvement~* intestinal obstruction or pseudo-obstruction~* Patients presenting diarrhoea plus fever or bloody stools~* Positivity to clostridium difficile toxin~* Severe hepatic or renal impairment~* Presence of severe cardiac insufficiency~* Hypersensitivity to rifamycin antimicrobial agents~* other conditions that would interfere or prevent the study completion~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin delayed release tablets (Type: EXPERIMENTAL): Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets twice a day for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of prostate cancer~* Demonstrates metastatic CRPC~* Castrate level of serum testosterone at screening~* Adequate hematologic, renal, and hepatic function~* ECOG status ≤1~* Life expectancy of at least 3 months~* No more than one prior course of cytotoxic chemotherapy~Exclusion Criteria:~* Pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histology~* Visceral metastasis excluding lymph nodes~* Use of opiate analgesics for prostate cancer pain or non-cancer pain~* other investigational agents or concurrent anticancer therapy other than standard androgen deprivation therapy within 4 weeks~* History of bleeding disorder~* History of seizure disorder~* Concomitant use of warfarin~* Prior exposure to PCUR-101~* History of myocardial infarction, arterial thrombotic events, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia~* Received wide-field external beam radiation therapy within 4 weeks~* Moderate to severe neuropathy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCUR-101 Dose Escalation (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
- PCUR-101 Dose Expansion Cohort 1 (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in 28 day cycles
- PCUR-101 Dose Expansion Cohort 2 (Type: EXPERIMENTAL): PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
- PCUR-101 Dose Expansion Cohort 3 (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 years or older~* Female subjects must be using a form of contraception~* \>1 seizures per month~* EEG confirmation of seizure activity (no non-epileptic seizures)~* Agrees to comply with study procedures, and keep seizure diary~* Agrees not to make any major deviations from current diet (especially fish intake) or medications (type, dosage)~* Agrees to having portions of blood samples stored for assays~* Has given voluntary, written, informed consent to participate in the study~Exclusion Criteria:~* Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial~* Use of significant amounts of fish oil or flax oil (omega-3) supplements within 8 weeks of the study.~* Allergy or sensitivity to fish, fish oil, coconut oil, olive oil, hemp oil, safflower oil, flax seed oil, or soybean oil~* Cognitive impairment (I.Q. below 70) and/or inability to give informed consent.~* Failure to understand English~* Subjects taking regular warfarin or aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fish Oil (Type: EXPERIMENTAL): Each capsule contains 625 mg of fish oil (100 mg EPA \& 250 mg DHA). Participants will take 12 capsules per day over 6 months.
- Safflower Oil (Type: PLACEBO_COMPARATOR): Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues